Andrographolide analogues are agonists of the estrogen receptor alpha in vitro and in vivo | Synapse
March 3, 2026
Andrographolide analogues are agonists of the estrogen receptor alpha in vitro and in vivo
Key Points
Andrographolide analogues significantly activate the estrogen receptor alpha, enhancing its activity in various cellular contexts.
In vitro experiments showed that these analogues lead to a measurable increase in receptor activation levels observed through specific assays.
Analysis across multiple biological systems confirmed that the agonistic properties of these compounds are consistent in vivo, suggesting stability and efficacy.
Supports further exploration of andrographolide analogues as potential treatment options for conditions related to estrogen signaling.